These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27372312)

  • 1. Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management.
    Fang F; Sun H; Wang Z; Ren M; Calabrese JR; Gao K
    CNS Drugs; 2016 Sep; 30(9):845-67. PubMed ID: 27372312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
    Gao K; Ganocy SJ; Gajwani P; Muzina DJ; Kemp DE; Calabrese JR
    J Clin Psychiatry; 2008 Feb; 69(2):302-9. PubMed ID: 18211129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
    Bai Y; Yang H; Chen G; Gao K
    J Clin Psychopharmacol; 2020; 40(2):167-179. PubMed ID: 32134852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm.
    Citrome L
    J Clin Psychopharmacol; 2017 Apr; 37(2):138-147. PubMed ID: 28141623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
    Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Hsu TW; Liang CS
    BMJ Ment Health; 2023 Feb; 26(1):. PubMed ID: 36789916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
    Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
    J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat.
    Gao K; Yuan C; Wu R; Chen J; Wang Z; Fang Y; Calabrese JR
    Neurosci Bull; 2015 Oct; 31(5):572-88. PubMed ID: 26024955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.
    Mauri MC; Paletta S; Di Pace C; Reggiori A; Cirnigliaro G; Valli I; Altamura AC
    Clin Pharmacokinet; 2018 Dec; 57(12):1493-1528. PubMed ID: 29915922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
    Hill L; Lee KC
    Ann Pharmacother; 2013 Jan; 47(1):75-89. PubMed ID: 23341158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
    Leucht S; Samara M; Heres S; Patel MX; Woods SW; Davis JM
    Schizophr Bull; 2014 Mar; 40(2):314-26. PubMed ID: 24493852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain and antipsychotics: a drug safety review.
    Musil R; Obermeier M; Russ P; Hamerle M
    Expert Opin Drug Saf; 2015 Jan; 14(1):73-96. PubMed ID: 25400109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method.
    Leucht S; Samara M; Heres S; Patel MX; Furukawa T; Cipriani A; Geddes J; Davis JM
    Schizophr Bull; 2015 Nov; 41(6):1397-402. PubMed ID: 25841041
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.